DiaMedica Therapeutics (DMAC) EBIT (2018 - 2019)
Historic EBIT for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q4 2019 value amounting to -$2.8 million.
- DiaMedica Therapeutics' EBIT fell 3084.55% to -$2.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$11.6 million, marking a year-over-year decrease of 7149.41%. This contributed to the annual value of -$26.7 million for FY2024, which is 2545.73% down from last year.
- Latest data reveals that DiaMedica Therapeutics reported EBIT of -$2.8 million as of Q4 2019, which was down 3084.55% from -$2.7 million recorded in Q3 2019.
- In the past 5 years, DiaMedica Therapeutics' EBIT ranged from a high of -$1.3 million in Q1 2018 and a low of -$3.4 million during Q1 2019